Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cardiac magnetic resonance imaging in patients referred for premature ventricular contractions: identifying patients most likely to benefit.

Frontiers in cardiovascular medicine·2026
Same author

Erratum: Author Correction to "Vaccination in Patients With Cardiovascular Disease: A Case-based Approach and Contemporary Review [Canadian Journal of Cardiology Open. Volume 7, Issue 10 (2025), 1375-1388]".

CJC open·2026
Same author

GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review.

Drugs in context·2026
Same author

Beyond reactive surveillance: Can machine learning finally personalize heart transplant care?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Changes in Pulmonary Artery Pressure Following Initiation of Guideline-Directed Medical Therapies in Patients With Heart Failure: Insights From GUIDE-HF.

Circulation. Heart failure·2026
Same author

Drug Adherence After Hospitalisation for Heart Failure: What Have We Learned from a French Survey?

Journal of clinical medicine·2026

相关实验视频

Updated: Jul 5, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

埃纳拉普利尔可降低慢性心力衰竭患者糖尿病的发生率:来自左心室功能障碍研究 (SOLVD) 的见解.

Emmanuelle Vermes1, Anique Ducharme, Martial G Bourassa

  • 1Department of Medicine, Montreal Heart Institute, Montreal, Canada.

Circulation
|March 12, 2003
PubMed
概括

恩拉普利尔是一种血管激素转化酶 (ACE) 抑制剂,可显著降低左心室功能障碍患者新发糖尿病的发生率. 这种保护作用在基线时禁食血葡萄糖水平受损的个体中尤为明显.

更多相关视频

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

相关实验视频

Last Updated: Jul 5, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

科学领域:

  • 心脏病学 心脏病学
  • 内分泌学 在内分泌学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 糖尿病是心力衰竭患者发病率和死亡率的重要危险因素.
  • 血管激素转化酶 (ACE) 抑制剂在患有左心室功能障碍的患者中预防糖尿病的潜力仍然在很大程度上未被探索.
  • 这项研究调查了ACE抑制剂埃纳拉普利尔对蒙特利尔心脏研究所左心室功能障碍研究 (SOLVD) 队列中的糖尿病发病率的影响.

研究的目的:

  • 追溯评估埃纳拉普利尔对患有左心室功能障碍的患者糖尿病发展的影响.
  • 为了确定埃纳拉普利能否在这个高风险人群中预防或延迟糖尿病的发病.

主要方法:

  • 来自蒙特利尔心脏研究所SOLVD参与者的临床图表的回顾性分析.
  • 禁食血葡萄糖 (FPG) 水平由盲目审查员评估.
  • 糖尿病诊断标准:FPG≥126 mg/dL (7 mmol/L) 至少两次,平均随访时间为2.9年.

主要成果:

  • 在291名非糖尿病患者中,有153人接受埃纳拉普利尔,138人接受安慰剂.
  • 9名 (5.9%) 接受埃纳拉普利的患者患上糖尿病,而31名 (22.4%) 接受安慰剂 (P<0.0001).
  • 多变量分析证实埃纳拉普利是降低糖尿病风险的强有力的预测因素 (HR 0.22;P<0.0001).
  • 在基线FPG受损的患者中,以纳拉普利的使用导致1名 (3.3%) 和12名 (48.0%) 的安慰剂患者糖尿病 (P<0.0001).

结论:

  • 埃纳拉普利尔在患有左心室功能障碍的患者中显示出显著的保护作用,防止糖尿病的发展.
  • 埃纳拉普利尔的益处尤其显著,在患有早已存在的禁食血葡萄糖水平受损的个体中.
  • 这些发现表明ACE抑制剂在心脏病患者的糖尿病预防策略中可能发挥作用.